Definium Therapeutics DFTX
$28.34 −$1.14 (-3.87%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.05 -1.02%
Open$29.14
Prev close$29.48
Day range$28.18 – $29.51
Volume3.24M
Market cap$3.88B
P/E (TTM)–
Dividend yield–
DFTX Stock News
Headlines matching Definium Therapeutics or the DFTX ticker, most recent first.
- LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
- CCORF Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $64
- LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $78
- Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
- Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $67 Positive
- Maxim Group Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $55
- JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $90
- A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91
- RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $66
- A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $50 to $75
- Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60
- Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72
- BofA Securities Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
- BofA Securities Initiates Definium Therapeutics(DFTX.US) With Buy Rating, Announces Target Price $75
- Piper Sandler Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $75
No comments yet — be the first to weigh in on DFTX.
Sign in to join the discussion.